# Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

> **NCT04019717** · PHASE2 · COMPLETED · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Hepatitis C
- Hepatitis C, Chronic
- Chronic Hepatitis C
- Hepatitis C Virus Infection
- HCV Infection

## Interventions

- **DRUG:** AT-527
- **DRUG:** Daclatasvir

## Key facts

- **NCT ID:** NCT04019717
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-20
- **Primary completion:** 2020-01-29
- **Final completion:** 2020-03-23
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04019717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04019717, "Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04019717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*